115 related articles for article (PubMed ID: 24805855)
1. TNF-α receptor 1 expression predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Tsuji M; Akioka T; Miyoshi T; Hirata Y; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Hanafusa T
Am J Surg Pathol; 2014 Aug; 38(8):1138-46. PubMed ID: 24805855
[TBL] [Abstract][Full Text] [Related]
2. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Hirata Y; Akioka T; Miyoshi T; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
Am J Surg Pathol; 2014 Feb; 38(2):228-34. PubMed ID: 24145654
[TBL] [Abstract][Full Text] [Related]
3. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
4. Focal adhesion protein expression in human diffuse large B-cell lymphoma.
Bosch R; Dieguez-Gonzalez R; Moreno MJ; Gallardo A; Novelli S; Espinosa I; Céspedes MV; Pavón MÁ; Briones J; Grañena A; Sierra J; Mangues R; Casanova I
Histopathology; 2014 Jul; 65(1):119-31. PubMed ID: 24467224
[TBL] [Abstract][Full Text] [Related]
5. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
6. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
7. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
[TBL] [Abstract][Full Text] [Related]
8. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
9. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
Shim H; Oh JI; Park SH; Jang S; Park CJ; Huh J; Suh C; Chi HS
J Clin Pathol; 2013 May; 66(5):420-5. PubMed ID: 23610041
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
[TBL] [Abstract][Full Text] [Related]
14. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
[TBL] [Abstract][Full Text] [Related]
15. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.
Wei X; Huang F; Wei Y; Jing H; Xie M; Hao X; Feng R
Leuk Res; 2014 Jun; 38(6):694-8. PubMed ID: 24713260
[TBL] [Abstract][Full Text] [Related]
16. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis.
Ma XB; Zheng Y; Yuan HP; Jiang J; Wang YP
Hum Pathol; 2015 Apr; 46(4):593-9. PubMed ID: 25682152
[TBL] [Abstract][Full Text] [Related]
17. High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.
Kuusisto ME; Haapasaari KM; Turpeenniemi-Hujanen T; Jantunen E; Soini Y; Peroja P; Bloigu R; Karihtala P; Kuittinen O
J Clin Pathol; 2015 Jul; 68(7):552-6. PubMed ID: 25935550
[TBL] [Abstract][Full Text] [Related]
18. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
19. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382
[TBL] [Abstract][Full Text] [Related]
20. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]